How Allgenesis Evaluated Unique Endpoints to Advance its Phase 2 DME Study

In this webinar, Sally Tucker, President of Global Services for Lexitas, is joined by the leadership team of Voxeleron and Allgenesis to discuss their collaboration on a recent Phase 2 study for diabetic macular edema (DME). The panelists highlight the importance of imaging and biomarkers in ophthalmology clinical trials and share their experiences working with Lexitas’ in-house Reading Center and Voxeleron’s AI technology.

The panelists discuss the value of real-time access to data, the role of biomarkers in assessing drug efficacy, and the benefits of post-hoc analysis. Additionally, they emphasize the need for a responsive and flexible reading center that can handle multiple imaging formats. Overall, the webinar provides valuable insights into the use of imaging and biomarkers in ophthalmology clinical trials.

Panelists

• Tan Nguyen: Vice President of Research and Development at Allgenesis Biotherapeutics
• Janet Cheatham: Clinical Consultant at Allgenesis
• Sunil Patel: Advisory Board Member at Allgenesis
• Daniel Russakoff: Chief Technology Officer at Voxeleron

Our Visionary Insights newsletter is published once a month and has thousands of subscribers. To stay in touch, subscribe today.